HK1202539A1 - (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel - Google Patents

(r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel Download PDF

Info

Publication number
HK1202539A1
HK1202539A1 HK15103057.7A HK15103057A HK1202539A1 HK 1202539 A1 HK1202539 A1 HK 1202539A1 HK 15103057 A HK15103057 A HK 15103057A HK 1202539 A1 HK1202539 A1 HK 1202539A1
Authority
HK
Hong Kong
Prior art keywords
nifuratel
synthesis
infections
treatment
disclosed
Prior art date
Application number
HK15103057.7A
Other languages
English (en)
Chinese (zh)
Inventor
‧加利亞爾迪
S‧加利亚尔迪
‧孔松尼
A‧孔松尼
‧美蘭德
F‧美兰德
‧布爾蓋羅尼
A‧布尔盖罗尼
Original Assignee
波利化学公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47846051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1202539(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 波利化学公司 filed Critical 波利化学公司
Publication of HK1202539A1 publication Critical patent/HK1202539A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C241/02—Preparation of hydrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HK15103057.7A 2012-05-11 2013-03-13 (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel HK1202539A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12167640.7 2012-05-11
EP20120167640 EP2662371A1 (en) 2012-05-11 2012-05-11 (R)-Nifuratel and synthesis of (R) and (S)-Nifuratel
PCT/EP2013/055078 WO2013167295A1 (en) 2012-05-11 2013-03-13 (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel

Publications (1)

Publication Number Publication Date
HK1202539A1 true HK1202539A1 (en) 2015-10-02

Family

ID=47846051

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103057.7A HK1202539A1 (en) 2012-05-11 2013-03-13 (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel

Country Status (27)

Country Link
US (2) US9284306B2 (enExample)
EP (2) EP2662371A1 (enExample)
JP (1) JP2015515998A (enExample)
KR (1) KR20150008871A (enExample)
CN (1) CN104379580A (enExample)
AU (1) AU2013258385A1 (enExample)
BR (1) BR112014027953A2 (enExample)
CA (1) CA2869827A1 (enExample)
CL (1) CL2014002951A1 (enExample)
CO (1) CO7131368A2 (enExample)
CR (1) CR20140505A (enExample)
DO (1) DOP2014000252A (enExample)
EA (1) EA201492081A1 (enExample)
EC (1) ECSP14026432A (enExample)
GE (2) GEP201606595B (enExample)
HK (1) HK1202539A1 (enExample)
IL (1) IL235429A0 (enExample)
IN (1) IN2014DN09256A (enExample)
MA (1) MA20150279A1 (enExample)
MX (1) MX2014013759A (enExample)
NZ (1) NZ700752A (enExample)
PE (1) PE20150167A1 (enExample)
PH (2) PH12014502500B1 (enExample)
SG (2) SG11201406447SA (enExample)
TN (1) TN2014000430A1 (enExample)
WO (1) WO2013167295A1 (enExample)
ZA (1) ZA201407596B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108254453A (zh) * 2016-12-28 2018-07-06 苏州电器科学研究院股份有限公司 一种有效测定塑料制品中邻苯二甲酸酯含量的检测方法
US10301319B2 (en) 2017-09-20 2019-05-28 Ph Pharma Co., Ltd. Thailanstatin analogs
CN108760950B (zh) * 2018-04-25 2022-07-15 国检测试控股集团京诚检测有限公司 一种测定硝基呋喃代谢物的方法
CN111892557B (zh) * 2019-05-05 2022-11-08 河北圣泰材料股份有限公司 哌嗪类成膜离子液体的合成方法
CN110672765B (zh) * 2019-10-11 2022-03-18 温州海鹤药业有限公司 一种定量检测硝呋太尔中顺式异构体杂质的方法
CN112457304B (zh) * 2020-12-07 2022-03-11 中国药科大学 一种硝呋太尔的制备方法
CN113828243B (zh) * 2021-09-14 2022-06-28 南京南大药业有限责任公司 一种硝呋太尔制霉菌素栓制造方法及设备
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
CN116947838B (zh) * 2023-07-25 2025-08-19 北京金城泰尔制药有限公司沧州分公司 高纯度硝呋太尔的生产方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL295684A (enExample) 1962-08-01
CN100506820C (zh) 2006-03-16 2009-07-01 韩志强 (s)-硝呋太尔,其制备方法和应用
CN100516063C (zh) * 2006-03-16 2009-07-22 韩志强 硝呋太尔的生产方法
CN101434584A (zh) * 2007-11-15 2009-05-20 中山大学 具有抗菌活性的手性噁唑烷酮类化合物
EP2243482A1 (en) * 2009-04-20 2010-10-27 Polichem SA Use of nifuratel to treat infections caused by atopobium species

Also Published As

Publication number Publication date
WO2013167295A1 (en) 2013-11-14
NZ700752A (en) 2016-02-26
PH12014502500A1 (en) 2014-12-15
JP2015515998A (ja) 2015-06-04
ECSP14026432A (es) 2015-09-30
SG11201406447SA (en) 2014-11-27
PE20150167A1 (es) 2015-02-07
TN2014000430A1 (en) 2016-03-30
EA201492081A1 (ru) 2015-06-30
BR112014027953A2 (pt) 2018-02-06
DOP2014000252A (es) 2014-12-31
IN2014DN09256A (enExample) 2015-07-10
US20150148547A1 (en) 2015-05-28
ZA201407596B (en) 2016-05-25
US20150119431A1 (en) 2015-04-30
EP2662371A1 (en) 2013-11-13
CN104379580A (zh) 2015-02-25
US9284306B2 (en) 2016-03-15
MA20150279A1 (fr) 2015-08-31
PH12014502500B1 (en) 2014-12-15
GEP201706626B (en) 2017-02-10
GEP201606595B (en) 2017-01-10
CA2869827A1 (en) 2013-11-14
SG10201608485XA (en) 2016-12-29
CR20140505A (es) 2015-02-06
MX2014013759A (es) 2015-08-07
AU2013258385A1 (en) 2014-10-30
PH12015502241A1 (en) 2016-08-15
CO7131368A2 (es) 2014-12-01
US9067927B2 (en) 2015-06-30
CL2014002951A1 (es) 2014-12-26
KR20150008871A (ko) 2015-01-23
EP2847189A1 (en) 2015-03-18
IL235429A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
HK1202539A1 (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
WO2012019426A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2012019430A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
HK1215579A1 (zh) 被取代的2，3-二氫苯並呋喃基化合物和其用途
WO2012046030A3 (en) Phosphodiesterase inhibitors
GEP201606598B (en) Heteroaromatic compounds as dopamine d1 ligands
HK1206028A1 (en) Phenicol antibacterials
WO2011039735A3 (en) Compounds with ddx3 inhibitory activity and uses thereof
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
WO2014147182A3 (en) Substituted n-biphenyl-3-acetylamino-benzamides and n-[3-(acetylamino)phenyl]-biphenyl-carboxamides and their use as inhibitors of the wnt signalling pathway
WO2014036502A8 (en) Tetracycline compounds
WO2015042414A8 (en) Multicyclic compounds and methods of using same
EP3722277A3 (en) 3'end caps for rna-interferring agents for use in rna
WO2015002755A3 (en) Compounds for the treatment of malaria
WO2008098143A3 (en) Antimicrobial compounds and methods of use
WO2015082590A3 (en) Bis-mmf derivatives
WO2015044434A3 (de) FLUOR-9-METHYL-ß-CARBOLINE
HK1202117A1 (en) Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an so2-containing group as vanilloid receptor ligands
WO2014096300A3 (en) Antibacterial compounds
WO2014006601A3 (en) Nanoparticle compositions of antibacterial compounds and other uses thereof
WO2015181837A3 (en) Novel compounds as anti-tubercular agents
WO2010139411A3 (de) 17β-ALKYL-17α-OXY-ESTRATRIENE